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The Search for the Best Stem Cell Continues*Lina Badimon, PHD,yz Gemma Vilahur, DVM, PHDySEE PAGE 1681C ell-based regenerative therapies have em-erged as one of the most promising treat-ment options for patients experiencing
ischemic heart disease and heart failure. Different
stem and progenitor cell types have been highly effec-
tive in numerous preclinical studies, encouraging
their clinical testing. Among these, bone marrow
(BM)-derived stem or endothelial progenitor cells
have been the most widely investigated. However,
clinical meta-analyses have reported a modest 3%
improvement (range 1.9% to 4.5%) in left ventricle
ejection fraction, indicating that transition to the
clinic may have occurred too quickly (1–3). In a few
trials, subfractions of BM-derived mononuclear cells
(MNCs), such as CD34þ hematopoietic stem cells
and CD133þ endothelial progenitor cells, were sorted
out before transplantation, resulting in ambivalent
outcomes. Certainly, several essential issues and
challenges need to be resolved to improve the thera-
peutic effects of cell-based therapies. Efforts should
focus on elucidating the mechanisms of cell therapy,
discovery of the ideal cell type, and the optimal
timing, dose, and mode of delivery, as well as the
impact of the microenvironment of the target tissue
on stem cell survival and engraftment.
It is a prevailing thought that BM-derived stem
cell therapeutic effects are primarily mediated
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Dr. Vilahur).enhance angiogenesis and stimulate the response of
endogenous stem cells, rather than regeneration of the
damaged tissue (e.g., transdifferentiation). In
this regard, Kim et al. (4) recently demonstrated the
high vessel-forming activity of a human-derived
CD31þ-enriched BM-stem cell fraction both in
vitro and in vivo (mouse model of hindlimb ischemia)
(5). CD31 (platelet endothelial cell adhesion mole-
cule [PECAM]-1) is a cell adhesion molecule expressed
in endothelial cells, platelets, and various hemato-
poietic/progenitor cells that was recently shown to
serve as a BM-MNC marker.In their study in this issue of the Journal, Kim
et al. (6) sought to determine culture conditions
capable of enhancing the reparative potential of
this CD31þ-enriched stem cell subpopulation. To
that end, the investigators ﬁrst compared the
adhesive, vasculogenic/angiogenic, proliferative, and
anti-inﬂammatory properties of CD31þ-BM-MNCs
cultured for 10 days under 3 different culture condi-
tions. Endothelial, mesenchymal, and hematopoietic
cell culture conditions were tested. The investigators
observed that culture conditions enhanced the BM-
derived CD31þ cells’ gene expression of integrins
and angiogenic and anti-inﬂammatory factors and,
conversely, reduced their expression of inﬂamma-
tory genes as compared with uncultured CD31þ cells.
Endothelial cell culture conditions yielded CD31þ
cells with the highest potency. Of note, the in-
vestigators reported that CD31 was expressed in
97.5% of uncultured cells, whereas CD31 expression
was reduced to 92.8% and 89.1% of cells cultured
under endothelial and mesenchymal culture condi-
tions, respectively (6). Taking into consideration that
CD31 expression decreases as both hematopoietic
stem and progenitor cells differentiate (7), this trend
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1696toward lower CD31þ expression on culture could
suggest that culturing drives cells toward a more
differentiated cell state with lower reparative
capacity.
The investigators further translated their observa-
tions in vitro into a nude mouse model of hindlimb
ischemia. Amelioration in vascular perfusion and a
reduced score of limb loss was observed using
cultured CD31þ cells as compared with uncultured
CD31þ cells, with endothelial cell culture conditions
producing cells that conferred the best vascular
recovery.
The investigators also reported on the capability of
cultured and uncultured CD31þ-BM-MNCs to further
attenuate cardiac remodeling and functional impair-
ment after myocardial infarction (MI). They observed
lower ﬁbrosis and improvement in left ventricular
fractional shortening, left ventricular end-systolic
dimension, and left ventricular end-diastolic dimen-
sion with the CD31þ-BM-MNCs. These observations
(as seen previously in other studies) highlight that
functional data other than left ventricle ejection
fraction should be regarded as primary endpoints in
cell therapy studies.
On the basis of all of these favorable observations,
and considering that adhesion is a prerequisite for
cell survival, we would expect long-term cell via-
bility, transdifferentiation, and neovascularization of
endothelial cultured CD31þ cells. This is exactly what
the investigators observed, with a superior potency
of engraftment and endothelial transdifferentiation
and a rather impressive improvement in capillary
density in both the ischemic hindlimb muscle and
the myocardial peri-infarct area in those animals
implanted with endothelial-cultured CD31þ cells.
Most importantly, this is observed for up to 1 year
after transplantation, indicative of additional bene-
ﬁts against the development of heart failure. The
investigators provided further relevant data sup-
porting this long-term viability in the form of a
higher survival rate in mice receiving endothelial
cell-cultured CD31þ cells.
The rate of endothelial transdifferentiation is
markedly higher in the hindlimb muscle compared
with the jeopardized myocardium (8% vs. 1.5%),
which may suggest that endothelial cultured CD31þ
cells would be more beneﬁcial in the setting of crit-
ical limb ischemia or intractable wounds than in the
setting of acute MI. Differences in the microenvi-
ronment of the target tissue where cells are placed
cannot be overlooked. Indeed, the transdifferen-
tiation capacity of stem cells depends on their ability
to survive and engraft in a hostile milieu. In this re-
gard, because of the presence of hypoxia, acidosis,the burst of inﬂammatory mediators, and reactive
oxygen species, acutely injured myocardium is con-
sidered to present a less friendly microenvironment
than peripheral tissues, which (in addition to the
constant beating of the heart and cardiomyocyte
tight junctions) lessens cell engraftment. Neverthe-
less, it should be taken into account that in the
present study, Kim et al. (6) implanted endothelial
cultured CD31þ-enriched cells just after the induction
of MI, an experimental approach not feasible in the
clinical scenario of autologous stem cell administra-
tion. Thus far, the majority of clinical trials have
involved patients’ own BM-derived cells. Therefore,
clinical testing of cultured endothelial CD31þ cells
would imply a 10-day gap between stem cell isolation
and administration. This period would allow atten-
uation of the harsh environment of the postischemic
heart, likely resulting in higher endothelial cell
transdifferentiation. No consensus exists as to the
optimal time of stem cell delivery. However, it is
widely accepted that stem cell therapy for post-MI
cardiac repair should be conducted within 1 to
2 weeks after the event, just after the intensive
inﬂammatory reaction occurs but before scar
formation.
Before moving toward clinical applications, it is
necessary to explore the impact of the patient’s dis-
ease state on hampering endothelial cell culture
preconditioning of CD31þ cells. Besides the poor host
response related to age and the presence of cardio-
vascular disease, compelling data from various
groups suggest that, depending on the patient’s
clinical condition, the stem cell reservoir may have a
lower capacity for therapeutic repair (8–12). Whether
culture of CD31þ cells isolated from BM of patients
with cardiovascular disease is able to overcome
the detrimental effects of disease on stem cell po-
tential must be addressed. Likewise, efforts should
focus on elucidation of the mechanisms by which
this occurs to compensate for stem cell functional
impairment. This information may represent a new
paradigm in the use of autologous stem cells sour-
ces. Although some allogeneic cell products present
low immunogenicity, they do not exclude immune
rejection. Hence, modiﬁcation of the selected ideal
stem cell population (engineered cells) before
transplantation to enhance the efﬁcacy of stem
cell therapy for future development should be
considered.
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